Huahai Pharmaceutical announced that Huaotai, a subsidiary of the company, and Huabo Biotech have received a drug clinical trial approval notice for new indications of HB0056 injection issued by the State Drug Administration and agreed to carry out clinical trials for chronic obstructive pulmonary disease indications.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.